Bill and Melinda Gates Foundation
Dr. Salim Abdulla: The Heart and Soul of Malaria Research
Dr. Salim Abdulla is a distinguished clinical epidemiologist whose remarkable career has significantly impacted the global fight against malaria and emerging pathogens. With over 20 years of experience in conducting clinical trials and groundbreaking research, he has played a pivotal role in shaping national malaria policies and leading innovations in healthcare.
Throughout his career, Dr. Abdulla has focused on evaluating and introducing critical interventions in the fight against malaria. He conducted extensive research on insecticide-treated bednets (ITNs) and artemisinin-based combination therapies, leading to important advancements in national malaria policy formulation. Notably, he is currently engaged in the evaluation of new malaria vaccines and treatments, with the goal of achieving regulatory licensure.
The Economics of Malaria
In the 2022 World Malaria Report, compiled by the World Health Organization (WHO), the total spend on funding the fight of malaria in 2021 was estimated at USD 3.5 billion. Over that year, the same report states that there were an estimated 247 million cases of malaria and 619,000 malaria deaths globally.
More recently, over the course of the 20th Century, malaria is believed to have claimed between 150–300 million lives. The disease is contracted predominantly in the tropical regions: sub-Saharan Africa, Asia and the Amazon basin. This is due to the prevalence of the Anopheles mosquito that transmits the disease. Poorer regions of Africa bear the vast majority of the burden. In 2021, around 95% of the diagnosed cases and deaths were on the African continent, 80% of which were children under the age of five. The disease is entirely preventable and curable with prompt diagnosis and effective methods of treatment which require sufficient investment and funding.
Aedes aegypti: Beyond the Black and White
One look at Aedes aegypti gives an immediate impression of its menacing nature. The telltale dark and white bands on the mosquito’s legs and other body parts bring a sense of foreboding and hardship. Sleek, silent, and stealthy, Ae. aegypti is the primary vector for several important, debilitating, and sometimes fatal human diseases including dengue, Zika virus, yellow fever, and chikungunya. The species is cause for mounting concern on many levels, as its biology, behavior, and ability to adapt have made Aedes aegypti one of the most pervasive and daunting public health challenges in the modern world.
The first mosquito ever associated with the spread of disease, Ae. aegypti is also the most studied of all mosquito species.1 From its humble beginnings in the African wild to a footprint that spans the globe, this durable and opportunistic insect has become a formidable opponent of vector control efforts worldwide.